PortViewPortView
Alvotech logo

Alvotech (ALVO) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$5.34+1.81%
1-year price historyRange $3.00 – $8.98
52-week range$5.34
$2.94$9.25

What Alvotech does

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Key metrics

Market cap
$1.80B
P/E (TTM)
-15.69
EPS (TTM)
$-0.34
Beta
0.18
Dividend yield
0.00%
Revenue / share
$1.38
50-day avg
$3.83
200-day avg
$4.15
52-week high
$9.25
52-week low
$2.94
CEO
Lisa Graver

ETFs linked to ALVO

Broad-market and Healthcare sector ETFs an investor holding Alvotech is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ALVO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ALVO in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Alvotech?
Alvotech trades under the ticker ALVO on NASDAQ.
Which exchange is ALVO listed on?
ALVO is listed on NASDAQ.
What sector does Alvotech operate in?
Alvotech is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze ALVO in a portfolio?
PortView shows ALVO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.